The Patent Finder

Terms ending in 2035

Glytec, LLC

Every in-force patent on Glytec, LLC's record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
PatentTitleHolderStatusExpiresConfidence
US 9,897,565System and Method for Optimizing Insulin Dosages for Diabetic Subjects
In force
 · High confidence
Glytec, LLCIn forceHigh confidence
US 11,311,213Insulin Management
In force
 · High confidence
Glytec, LLCIn forceHigh confidence
US 9,892,234Subcutaneous Outpatient Management
In force
 · High confidence
Glytec, LLCIn forceHigh confidence
US 10,128,002Subcutaneous Outpatient Management
In force
 · Medium confidence
Glytec, LLCIn forceMedium confidence
US 10,403,397Subcutaneous Outpatient Management
In force
 · Medium confidence
Glytec, LLCIn forceMedium confidence
US 11,678,800Subcutaneous Outpatient Management
In force
 · High confidence
Glytec, LLCIn forceHigh confidence
US 11,694,785A Method and Dosing Controller for Subcutaneous Outpatient Management
In force
 · Medium confidence
Glytec, LLCIn forceMedium confidence
US 12,023,127Subcutaneous Outpatient Management
In force
 · Medium confidence
Glytec, LLCIn forceMedium confidence
US 12,620,473A Method and Dosing Controller for Adminstering a Correction Dose of Insulin
In force
 · Medium confidence
Glytec, LLCIn forceMedium confidence
9 of 9 patents shown. Soonest term end first, then patent number.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited